CPRX CATALYST PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended March 31, 2026, CATALYST PHARMACEUTICALS INC reported revenue of $149M (up 5.6% from a year earlier), net income of $63.7M and diluted EPS of $0.50; over the last four quarters revenue was $597M and net income $221M; for the fiscal year ended December 2025 revenue was $589M, up 19.8% on the year before.

CPRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $589M, gross profit n/a, operating income $258M, net income $214M (margin 36.4%), EPS $1.68
• Fiscal year ended Dec 2024: revenue $492M, gross profit n/a, operating income $195M, net income $164M (margin 33.3%), EPS $1.31
• Fiscal year ended Dec 2023: revenue $398M, gross profit n/a, operating income $86.8M, net income $71.4M (margin 17.9%), EPS $0.63
• Fiscal year ended Dec 2022: revenue $214M, gross profit n/a, operating income $102M, net income $83.1M (margin 38.8%), EPS $0.75
• Fiscal year ended Dec 2021: revenue $141M, gross profit n/a, operating income $52.4M, net income $39.5M (margin 28.0%), EPS $0.37

CPRX quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $149M (up 5.6% year over year), net income $63.7M, EPS $0.50
• Quarter ended Dec 31, 2025 (from the annual report): revenue $153M (up 7.6% year over year), net income $52.7M, EPS $0.40
• Quarter ended Sep 30, 2025: revenue $148M (up 15.3% year over year), net income $52.8M, EPS $0.42
• Quarter ended Jun 30, 2025: revenue $147M (up 19.4% year over year), net income $52.1M, EPS $0.41
• Quarter ended Mar 31, 2025: revenue $141M (up 43.6% year over year), net income $56.7M, EPS $0.45
• Quarter ended Dec 31, 2024 (from the annual report): revenue $142M (up 28.3% year over year), net income $55.9M, EPS $0.44
• Quarter ended Sep 30, 2024: revenue $129M (up 25.3% year over year), net income $43.9M, EPS $0.35
• Quarter ended Jun 30, 2024: revenue $123M (up 23.2% year over year), net income $40.8M, EPS $0.33
• Quarter ended Mar 31, 2024: revenue $98.5M (up 15.4% year over year), net income $23.3M, EPS $0.19
• Quarter ended Dec 31, 2023 (from the annual report): revenue $111M (up 82.0% year over year), net income $34.8M, EPS $0.33
• Quarter ended Sep 30, 2023: revenue $103M (up 79.4% year over year), net income −$30.8M, EPS −$0.29
• Quarter ended Jun 30, 2023: revenue $99.6M (up 87.5% year over year), net income $37.8M, EPS $0.33
• Quarter ended Mar 31, 2023: revenue $85.4M (up 98.1% year over year), net income $29.6M, EPS $0.26
• Quarter ended Dec 31, 2022 (from the annual report): revenue $60.8M (up 58.6% year over year), net income $25.5M, EPS $0.23
• Quarter ended Sep 30, 2022: revenue $57.2M (up 59.2% year over year), net income $22.7M, EPS $0.20
• Quarter ended Jun 30, 2022: revenue $53.1M (up 46.1% year over year), net income $21.6M, EPS $0.20
• Quarter ended Mar 31, 2022: revenue $43.1M (up 42.7% year over year), net income $13.2M, EPS $0.12
• Quarter ended Dec 31, 2021 (from the annual report): revenue $38.3M, net income $9.31M, EPS $0.09
• Quarter ended Sep 30, 2021: revenue $36.0M, net income $10.3M, EPS $0.10
• Quarter ended Jun 30, 2021: revenue $36.4M, net income $12.2M, EPS $0.11

CPRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $209M, share buybacks $25.3M
• Fiscal year ended Dec 2024: operating cash flow $240M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow $144M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow $116M, share buybacks $6.91M
• Fiscal year ended Dec 2021: operating cash flow $60.4M, share buybacks $12.1M

CPRX balance sheet

• Mar 31, 2026: cash $756M, total assets $1.15B, total liabilities $135M, shareholders' equity $1.01B
• Dec 31, 2025: cash $709M, total assets $1.10B, total liabilities $150M, shareholders' equity $954M
• Sep 30, 2025: cash $690M, total assets $1.05B, total liabilities $131M, shareholders' equity $920M
• Jun 30, 2025: cash $653M, total assets $972M, total liabilities $116M, shareholders' equity $856M
• Mar 31, 2025: cash $581M, total assets $909M, total liabilities $115M, shareholders' equity $794M
• Dec 31, 2024: cash $518M, total assets $851M, total liabilities $124M, shareholders' equity $728M
• Sep 30, 2024: cash $442M, total assets $772M, total liabilities $111M, shareholders' equity $661M
• Jun 30, 2024: cash $376M, total assets $706M, total liabilities $97.7M, shareholders' equity $609M

What is CPRX's revenue?

CATALYST PHARMACEUTICALS INC reported $597M of revenue over its last four quarters, through March 31, 2026.

Is CPRX profitable?

Yes. CATALYST PHARMACEUTICALS INC earned $221M over the last four quarters.

What is CPRX's EPS?

Diluted earnings per share over the last four quarters were $1.73; $0.50 in the latest quarter.

CPRX ownership and insider trades · All stocks